Inotiv Inc 's (NOTV) Outlook - CSIMarket
CSIMarket
 
Inotiv Inc   (NASDAQ: NOTV)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 



  Inotiv Inc Outlook

On December 11 2023 the Inotiv Inc provided following guidance

Inotiv Inc. has released its financial results for the fourth quarter and full year of fiscal 2023, along with a business update. The company has reported a 4.5% increase in revenue for fiscal year 2023, reaching a total of $572.4 million. This achievement is in line with the revised guidance provided by the company.

During the past fiscal year, Inotiv Inc. has made significant progress in expanding its Drug Substance Analysis (DSA) capacity, developing new services, and reducing outsourcing. These accomplishments are expected to drive further growth in DSA revenues for fiscal year 2024.

Inotiv Inc. anticipates achieving the remainder of expected expense reductions in fiscal year 2024. This indicates the company's commitment to managing costs efficiently and improving its overall financial performance.

To discuss these financial results and business updates, Inotiv Inc. will be hosting a conference call starting at 4:30 pm ET today. This call will provide an opportunity for shareholders, investors, and s to gain further insights into the company's performance and future plans.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.